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Background
The last 10 years have seen a remarkable increase in the 
understanding of the biology of numerous primary brain 
tumors. This is also reflected by the most recent edition 
of the World Health Organization (WHO) classification 
of tumors of the central nervous system (CNS) which was 
released in 2016. In the new WHO classification, CNS tu-
mors are not only categorized based on histopathological 
features but for the first time also by additional molecular 
parameters [1]. Within the last decade, numerous high-
throughput analyses, e.g. within the Cancer Genome Atlas 
(TCGA) project [2], have been performed for different brain 
tumor entities. It can be safely assumed that the current 
edition of the WHO classification represents only the first 
step towards a detailed molecular characterization of many 
brain tumors and already now a plethora of specific molecu-
lar alterations in different CNS tumors has been recognized 
which have not yet entered the WHO grading system. In 
this overview, we summarize some key findings on the mo-
lecular level in the most common primary brain tumors 
with a particular focus on those alterations that are helpful 
for diagnostic purposes and clinical decision-making.
Diffuse Gliomas
A cornerstone in the molecular subclassification of glio-
mas was the identification of mutations in the isocitrate 
dehydrogenase (IDH) 1 and 2 genes. Sequencing revealed 
that the majority of WHO grade II and approximately 
60% of all WHO grade III gliomas harbor a mutation in 
either of the 2 genes [3]. In contrast, only a minority of 
glioblastomas displays an IDH mutation [4]. Because of 
their uniform presence across the tumor cell population 
in IDH mutation-positive tumors, IDH mutations are re-
garded as an early event during gliomagenesis. Across all 
WHO grades, IDH-mutated gliomas have a better prog-
nosis than their counterparts with IDH wild-type genes 
with similar histology [5]. IDH-mutant tumors are now 
generally considered to represent different disease enti-
ties, potentially overruling histological appearance, and 
the role of WHO grading versus that of other molecular 
markers within the tumor groups defined by IDH muta-
tion status needs to be reassessed. 
According to the new WHO classification, a 1p/19q co-
deletion, also referred to as loss of heterozygosity (LOH) 
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1p/19q, is mandatory to render the definite diagnosis of 
an oligodendroglial tumor. LOH 1p/19q is probably al-
ways associated with an IDH mutation. 1p/19q-codeleted 
tumors have a better prognosis than 1p/19q-intact glio-
mas and the predictive role of a 1p/19q co-deletion for 
benefit from polychemotherapy using procarbazine, vin-
cristine and lomustine (PCV) has been shown repeatedly 
in WHO grade III grade tumors [6, 7] and more recently 
in WHO grade II tumors [8].
In addition to these two major diagnostic markers stressed 
in the new WHO classification, IDH and 1p/19q codele-
tion status, the methylation status of the promoter region of 
the O6-methylguanine-DNA methyltransferase (MGMT) 
gene continues to impact clinical decision making in pa-
tients with diffuse gliomas of adulthood. MGMT confers 
resistance to alkylating agents such as temozolomide by 
removing treatment-induced DNA lesions [9]. It is now 
widely accepted that MGMT promoter methylation pre-
dicts benefit from alkylating agent chemotherapy in glio-
blastoma. There may also be a predictive role for MGMT 
in IDH wild-type lower-grade gliomas, but possibly not 
in IDH-mutated tumors [10]. Testing for MGMT status is 
done by methylation-specific PCR or by pyrosequencing. 
Since there is no alternative to temozolomide in the first-
line setting and since temozolomide is commonly well tol-
erated, younger patients with newly diagnosed glioblasto-
ma are still treated with a combination of radiotherapy and 
temozolomide chemotherapy independent of the MGMT 
promoter methylation status, although clinical trials with 
omission of temozolomide in the first-line setting for pa-
tients with tumors without MGMT promoter methyla-
tion are increasingly considered an option [11]. However, 
MGMT is a clinically useful marker for therapeutic deci-
sion making in elderly and frail patients who may not be 
eligible for combined modality treatment [12-14].
The comprehensive molecular profiling of gliomas has 
revealed many other biological alterations which are in-
creasingly used for diagnostic purposes. This includes 
mutations in the promoter region of the gene encoding 
telomerase reverse transcriptase (TERT) as well as mutations 
in the -thalassemia/mental-retardation-syndrome-X-linked 
(ATRX) gene which are frequently found in oligoden-
drogliomas and glioblastomas (TERT) respectively IDH-
mutant astrocytic tumors (ATRX) [15, 16]. Furthermore, 
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the newly defined group of «diffuse midline gliomas» is 
characterized by mutations in the H3F3A gene [17]. 
Other gliomas
Pilocytic astrocytomas
Pilocytic astrocytomas are rare in adults but represent 
frequent CNS tumors in the pediatric population. Simi-
lar to diffuse gliomas, their molecular landscape has been 
described in detail. Pilocytic astrocytomas may be con-
sidered a single-pathway disease with virtually all tumors 
harboring alterations in the mitogen-activated protein kinase 
(MAPK) pathway [18]. The most frequent finding is a fu-
sion between the KIAA1549 gene and the BRAF oncogene 
but there are also other mechanisms resulting in a MAPK 
activation. Targeting the activated pathway, e.g. by mitogen-
activated protein kinase kinases (MEK) inhibitors, is currently 
explored as a novel therapeutic approach in clinical trials.
Gangliogliomas and pleomorphic xanthoastrocytomas
BRAF mutations have been described in a subgroup of gan-
gliogliomas and xanthoastrocytomas. Similar to pilocytic 
astrocytomas, molecular testing for the activating BRAF 
mutation V600E is warranted in patients with progressive 
tumors that are no longer eligible for surgery or radiation 
therapy. Several case reports and retrospective series suggest 
that BRAF inhibition with vemurafenib or dabrafenib may 
result in clinically relevant anti-tumor activity [19].
Ependymomas
Ependymomas have been reclassified based on three differ-
ent localization patterns in the CNS: supratentorial, pos-
terior fossa and spinal, as well as based on DNA methy-
lation profiling, resulting in 9 subgroups of ependymal 
tumors [20]. The 2016 WHO classification has only par-
tially incorporated these novel findings. The presence of 
an oncogenic fusion between RELA and C11orf95 indi-
cates a supratentorial tumor with poor prognosis that is 
more frequent in children than in adults. Similar to other 
brain tumors, it can be expected that the detailed genetic 
profiling of ependymomas will result in a further segrega-
tion of these tumors into specific subgroups.
Subependymal giant cell astrocytomas
Subependymal giant cell astrocytomas (SEGA) are typical-
ly found in patients affected by tuberous sclerosis complex 
(TSC). This disease is characterized by a dysregulation of 
the mammalian target of rapamycin (mTOR) pathway be-
cause of an alteration in the TSC1 or TSC2 gene. mTOR 
inhibition using drugs such as everolimus has emerged as 
a powerful therapeutic approach that results in a reduc-
tion of SEGA volume and sustained growth inhibition in 
the majority of patients [21].
Meningiomas
Meningiomas account for approximately 35% of all pri-
mary brain tumors. They are mostly benign tumors that 
can be cured by surgical resection. However, some of 
these tumors display histological features of malignancy 
and also meningiomas categorized as WHO grade I tu-
mors may recur and rarely cause distant metastasis. In 
the last few years, several reports have described a set of 
gene mutations that are frequently found in meningiomas 
including mutations in AKT1, SMO, TRAF7, KLF4 and 
PIK3CA [22-24]. Some of these mutations correlate with 
histological subtypes and tumor localization in the brain 
[25]. So far, testing for these molecular alterations is not 
yet part of the standard diagnostic. However, since muta-
tions in the AKT1 or SMO gene may be actionable, genetic 
testing should be considered in patients who have run 
out of standard treatment options. It needs to be awaited 
whether the first successful reports on targeted therapy for 
patients with progressive meningioma [26] can be trans-
lated into standard treatment options in the future.
Craniopharyngiomas
The genetic profiling of craniopharyngiomas has identified 
distinct molecular alterations that are associated with the 
well-known histophathological subgroups. Adamantino-
matous craniopharyngiomas typically harbor a mutation 
of the beta-catenin gene (CTNNB1). Papillary craniopha-
ryngiomas do not display this mutation but virtually all 
have a BRAFV600E mutation [27]. The latter may represent 
a novel therapeutic target and clinical trials exploring the 
activity of BRAF inhibitors are ongoing.
Medulloblastomas
Medulloblastoma is typically located in the cerebellum and 
more frequently diagnosed in children than in adults. The 
molecular characterization of these tumors has resulted in 
4 different subgroups based on activations in the wingless 
(WNT) or sonic hedgehog (SHH) pathway as well as the 
groups 3 and 4 [28]. Medulloblastomas with an alteration 
in the WNT pathway have the best prognosis [29]. In the 
SHH subgroup, mutations in the p53 gene are associated 
with a particularly poor prognosis. Beyond its prognostic 
role, the molecular profiling may also be increasingly used 
for therapeutic decision-making. SHH-activated tumors 
may be sensitive to SMO inhibitors which may be used as 
an experimental treatment strategy in patients who have 
no further established treatment options. 
Summary and outlook
High-throughput studies have paved the road for a de-
tailed understanding of the molecular landscape of many 
brain tumors. Currently, only a small proportion of de-
tectable molecular alterations is clinically relevant for 
diagnostic and therapeutic purposes. Assessing the IDH 
and 1p/19q status is mandatory to render the diagnosis of 
an astrocytic or oligodendroglial tumor. Similarly, testing 
for the presence of a KIAA1549:BRAF fusion or H3F3A 
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mutation allows for increased diagnostic accuracy in some 
patients. The MGMT promoter methylation status can be 
used for clinical decision-making, particularly in patients 
with IDH wild-type tumors who are not eligible for com-
bined modality treatment. Although in-depth molecular 
characterization of brain tumors is feasible within a rea-
sonable time and exhibits profound diagnostic power [30], 
the number of actionable molecular alterations with an 
impact on therapeutic decisions is still limited. However, 
not only in gliomas but also other brain tumors such as 
meningiomas and medulloblastomas, further develop-
ments in the molecular characterization of these neo-
plasms as well as the emergence of novel drugs will result 
in more personalized and patient-tailored treatment ap-
proaches in the next years.
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